Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Luisa Fernanda Olaya A"'
Autor:
Tripti Joshi, Ruta Gupta, Brodie Hookins, Elizabeth L. Chua, Ash Gargya, Susan V. McLennan, Watson Zara, Joanne Malek, Luisa Fernanda Olaya A, Michael Elliott
Publikováno v:
Journal of the Endocrine Society
The study of miRNAs in PTC has shown that these molecules can help in the diagnosis, prognosis and also as therapeutic candidates [1]. miRNAs are known to be differentially expressed in PTC compared to non-cancerous tissue and a few studies have show
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c382336b2581c623e148d3fad11679ca
http://europepmc.org/articles/PMC7208698
http://europepmc.org/articles/PMC7208698
Autor:
Bing Yu, Elizabeth L. Chua, Ruta Gupta, Tripti Joshi, Susan V. McLennan, Luisa Fernanda Olaya A, Ash Gargya
Publikováno v:
Journal of the Endocrine Society. 5:A867-A868
There is limited data on prevalence of PD-L1 expression in papillary thyroid cancer (PTC). Anti- PD-L1 therapy is now being trialled for head and neck cancers including thyroid cancer. Whether presence of PD-L1 staining in PTC might result in a bette
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43229c134eaa31a68a9ac7b82340e7cc
https://doi.org/10.1210/jendso/bvab048.1771
https://doi.org/10.1210/jendso/bvab048.1771
Autor:
Elizabeth L. Chua, Bing Yu, Tripti Joshi, Luisa Fernanda Olaya A, Susan V. McLennan, Ruta Gupta
Publikováno v:
Journal of the Endocrine Society
PTC and melanoma are known to harbour common mutations, but this has not been extensively investigated. Targeted therapies for BRAF and PD-L1 have been used for melanoma and there are ongoing clinical trials for use of PD-L1 inhibitors in PTC but its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6087b75534d6670ca7b5879a78509686
https://doi.org/10.1210/jendso/bvab048.2102
https://doi.org/10.1210/jendso/bvab048.2102